Praetego
verb \ pruh-tay-go\
Latin “to protect”
Harnessing the Power of Protection
Praetego is a pharmaceutical company committed to protecting patients from neurodegeneration - from acute and chronic causes.
Praetego’s oral small molecules, the Amadorins, are neuroprotective. Through a novel mechanism of action, the Amadorins protect the nervous system from oxidative stress and glucotoxicity. Both contribute to the pathology of neurodegeneration. Our lead candidate, PTG-630, has demonstrated remarkable ability to protect the brain, in both animal models and human derived brain cells. Treatment with PTG-630 protected against and reversed cognitive decline in multiple animal models of neurodegeneration. This data is confirmed by target engagement and functional markers. After a successful Pre-IND meeting, PTG-630 is poised to start IND-enabling and then clinical trials
Our Purpose
Praetego was founded on extensive science and the desire to offer potent oral drugs that protect patients from neurodegeneration and age-related diseases. Our proprietary small molecule technology targets a primary initiator of oxidative stress, an established driver of brain injury, neurodegeneration and aging.
Our Pipeline
Our lead Amadorin asset is PTG-630. This potent oral candidate has demonstrated preclinical proof of efficacy in multiple models of neurodegeneration. It easily crosses the blood-brain barrier. It has a wide therapeutic index and an ideal safety profile. The Amadorins have comprehensive IP protection through 2045.